0001193125-24-006430.txt : 20240402 0001193125-24-006430.hdr.sgml : 20240402 20240111113600 ACCESSION NUMBER: 0001193125-24-006430 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: enGene Holdings Inc. CENTRAL INDEX KEY: 0001980845 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 BUSINESS PHONE: (514) 332-4888 MAIL ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 CORRESP 1 filename1.htm CORRESP

LOGO

Howard Kenny

+1.212.309.6843

howard.kenny@morganlewis.com

January 11, 2023

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

 

  Re:

enGene Holdings Inc.

Amendment No. 1 to Registration Statement on Form S-1

Filed December 15, 2023

File No. 333-275700

Ladies and Gentlemen:

On behalf of enGene Holdings Inc. (the “Company”), we submit this letter in response to comments from the staff (the “Staff”) of the United States Securities and Exchange Commission (the “Commission”) contained in its letter dated December 26, 2023 (the “December 2023 Letter”), relating to the above referenced Amendment No. 1 to the Registration Statement on Form S-1 filed December 15, 2023 (the “Amendment”), with respect to the Registration Statement on Form S-1 filed November 22, 2023 (the “Registration Statement”).

In advance of the Company’s filing of an Amendment No. 2 to the Registration Statement (the “Second Amendment”), we respectfully request that the Staff review supplementally proposed changes that address the comments from the Staff’s December 2023 Letter (the “Proposed Changes”). For your convenience, we have restated the Staff’s comments from the December 2023 Letter below in their entirety in bold, followed by the corresponding responses from the Company. The Proposed Changes are attached hereto as Exhibit A.

Cover Page

 

1.

We note your revisions in response to prior comment 1, please continue to revise to disclose the effective price per share paid for the common shares issued to the investors in the PIPE Financing and to the investors party to the Non-Redemption Agreement.

Response: In response to the Staff’s comment, the Company will revise the prospectus cover page and page 17, as shown on the Proposed Changes attached hereto.


2.

We note your revisions in response to prior comment 2 but do not see related disclosure in the prospectus summary or risk factors as requested. Please advise or revise as appropriate. In addition, as applicable, and as requested by prior comment 2, describe the impact on your liquidity and update the discussion on the ability of your company to fund your operations on a prospective basis with your current cash on hand.

Response: In response to the Staff’s comment, the Company will revise the prospectus cover page and pages 12, 16, 85, and 88, as shown on the Proposed Changes attached hereto. With respect to the impact on liquidity and the ability of the Company to fund operations of the Company with current cash on hand, the Company will provide an updated discussion of such matters in the Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MDA”) which will be revised to discuss results for the Company’s fiscal year ended October 31, 2023, and its financial condition as of October 31, 2023. The updated MDA will be included in the Second Amendment.

Risk Factors

Certain existing securityholders acquired their securities in enGene at prices below the current trading price of such securities..., page 83

 

3.

We note this risk factor provided in response to prior comment 4. As requested by that comment, also disclose that even though the current trading price is below the SPAC’s IPO price, the private investors have an incentive to sell because they will still profit on sales because of the lower price that they purchased their shares than the public investors.

Response: In response to the Staff’s comment, the Company will revise the risk factor on page 85, as shown on the Proposed Changes attached hereto.

* * * *

If you have any questions or comments regarding these responses or require any additional information, please do not hesitate to contact me at +1.212.309.6843 or Maria Sasinoski at +1.412.560.7482.

 

Very truly yours,

/s/ Howard Kenny


Exhibit A

Proposed Changes

GRAPHIC 2 g496651g0111201527807.jpg GRAPHIC begin 644 g496651g0111201527807.jpg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